JUBLPHARMA — Jubilant Pharmova Income Statement
0.000.00%
- IN₹152.72bn
- IN₹174.03bn
- IN₹82.80bn
Annual income statement for Jubilant Pharmova, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 61,302 | 62,817 | 67,029 | 72,345 | 82,796 |
| Cost of Revenue | |||||
| Gross Profit | 42,089 | 38,922 | 41,319 | 44,686 | 51,330 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 53,057 | 61,087 | 63,487 | 60,682 | 75,194 |
| Operating Profit | 8,245 | 1,730 | 3,542 | 11,663 | 7,602 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 6,304 | 278 | 1,705 | 9,806 | 6,141 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 4,130 | -649 | 727 | 8,363 | 3,975 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 4,139 | -610 | 771 | 8,394 | 3,985 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 4,139 | -610 | 771 | 8,394 | 3,985 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 26.1 | 5.6 | 9.39 | 33.5 | 27.5 |
| Dividends per Share |